gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · CRLTechnologyR&D — Physical & Biological Sciences

Charles River Laboratories International, Inc. (CRL)

$313.02−4.07%
Close Nov 5, 2026 · split-adjusted
Nov 2, 2026$338.54▲ 89.28% in range
Nov 3, 2025Low $149.93 · High $376.10Nov 2, 2026
What changed · written from our data
As of Nov 5, 2026

Charles River Laboratories International closed at $313.02 on Nov 5, down 4.07%, 16.8% below its 52-week closing high. Volume of 1.7M shares was 1.35× its 20-day average (above normal).

Split-adjusted performance: +4.2% over one month, +72.3% over six months, +76.0% over one year.

In the quarter ended Jun 27, 2026, revenue was $1B, down 2.7% from a year earlier, with a net margin of -0.1%.

Short interest was 2.8M shares at the Oct 15 settlement, down 1.5% from the prior report (6.0% of float, 2.9 days to cover).

Market cap$15.00B47.9M shares
Revenue · quarter$1.00B−2.7% YoY
Diluted EPS$-0.03−102.8% YoY
P/E · TTM—P/S 3.8×
Net margin-0.1%Gross 36.2%
Dividend yieldNone
52-week range149.93 – 376.10−16.8% from high
Volume1.7M1.35× 20-day avg
Volatility · 60d45.3%Annualised
Short % of float6.0%2.9 days to cover
Net cash-$2.43BCash $192.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −16.8%1M +4.2%3M +17.0%6M +72.3%YTD +56.9%1Y +76.0%3Y +85.9%5Y −28.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within R&D — Physical & Biological Sciences

Percentile among 11 companies (100 = best)

6-month momentum90
Revenue growth30
Net margin70
Value (low P/E)—
Size70

Industry medians: 6-month return +48.1%, revenue growth +8.5%, net margin −122.0%, P/E 47.0×.

Short interest

Details →
Shares short2.8M−1.5% vs prior
Days to cover2.9Settled Oct 15
% of float6.0%
Short vol. 10d46.5%of daily volume

Closest peers by size in R&D — Physical & Biological Sciences

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CRLCharles River Laboratories International$313.02−4.07%+72.3%−2.7%−0.1%—$15.00B
MEDPMedpace Holdings$634.98−3.32%+48.1%+8.5%19.2%34.3$17.76BCompare
INCYIncyte Genomics$118.01−3.94%+20.7%+14.0%−50.4%59.6$24.05BCompare
IQVIQVIA Holdings$264.88+0.41%+48.3%+8.0%7.9%31.3$43.65BCompare
ABSIAbsci$9.39−10.40%+63.3%−46.4%−10443.4%—$1.61BCompare
OABIOmniAb$4.83−6.76%+228.6%+78.3%−393.9%—$704.5MCompare
NRCNRC Health$25.48−5.87%+36.0%+11.0%12.3%88.2$540.7MCompare
MXCTMaxCyte$1.31−5.76%+50.3%−14.5%−122.0%—$135.2MCompare
IBACIB Acquisition$10.81−0.46%−0.2%———$54.1MCompare

News about Charles River Laboratories International

All news →
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?Zacks Investment Research · Oct 28, 2026NeutralGlobal Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCelleraGlobeNewswire Inc. · Oct 12, 2026▲ PositivePGNY or CRL: Which Is the Better Value Stock Right Now?Zacks Investment Research · Oct 7, 2026▼ NegativeCharles River Gains 75.8% in a Year: What's Driving the Rally?Zacks Investment Research · Oct 7, 2026NeutralPharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles RiverGlobeNewswire Inc. · Sep 29, 2026▲ Positive

Quick answers

What does Charles River Laboratories International do?
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world.
What is CRL's market cap?
$15B, based on the Nov 5 close of $313.02.
Does Charles River Laboratories International pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CRL is sold short?
2.8M shares, 6.0% of float, as of Oct 15, 2026.
What sector is CRL in?
Technology, in the R&D — Physical & Biological Sciences industry.

About Charles River Laboratories International

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.

HQ: Wilmington, MA19,700 employeesListed Jun 23, 2000criver.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology